New immunotherapy combo for advanced melanoma (first treatment)
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must carry a common immune system protein called HLA-A*02:01 (a simple blood test can tell).
- Your melanoma has spread to other parts of the body (Stage IV) or cannot be fully removed by surgery (unresectable Stage III).
- You have not had any prior cancer treatment for advanced melanoma (this trial is for first-line therapy).
- You are in good general health, able to do your daily activities without much trouble (ECOG score 0 or 1).
- You do not have an active autoimmune disease that requires immune-suppressing medication.
- You are willing to provide a tumor tissue sample (from a previous biopsy or a fresh one) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a combination of two drugs (iparomlimab and tuvonralimab) plus bevacizumab for people with advanced melanoma whose cancer got worse after prior immunotherapy. The goal is to see if this new combination can help when standard treatments stop working.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.